March 8, 2024
Loading...
You are here:  Home  >  'CytomX'
Latest

Amgen stock stable despite end of drug ban

By   /  Friday, October 13th, 2017  /  Latest news  /  Comments Off on Amgen stock stable despite end of drug ban

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen lawsuit over cholesterol drug will get new trial

By   /  Thursday, October 5th, 2017  /  Health Care & Life Science, Latest news, Technology  /  Comments Off on Amgen lawsuit over cholesterol drug will get new trial

An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →

Latest

CytomX to take venture money and run

By   /  Monday, October 4th, 2010  /  Top Stories  /  Comments Off on CytomX to take venture money and run

Santa Barbara-based biotech firm CytomX Therapeutics has raised $30 million in venture capital and announced plans to move to the San Francisco Bay Area by the end of the year. The company is developing technology that would help antibodies better target the disease tissue they’re intended for, reducing harmful side effects. It was founded by Read More →